Abstract
We examined whether cerebrovascular white matter pathology is related to cognition as measured by the compound score of CERAD neuropsychological battery in cognitively normal older adults, patients with mild cognitive impairment, and patients with Alzheimer’s disease (total
INTRODUCTION
Aging is often associated with vascular white matter (WM) brain pathology [1]. The functional consequences of these brain changes are related to their severity and extent, and can range from almost none via mild cognitive decline to dementia. Furthermore, comorbid vascular brain changes are often present in patients with Alzheimer’s disease (AD) [2], with a number of WM pathways having been implicated as manifesting significant degeneration in AD [3]. Additionally, cerebrovascular risk factors such as hypertension, smoking, and diabetes are also risk factors for AD [4].
Some studies have examined the effects of vascular brain changes on cognitive function in mild cognitive impairment (MCI) and AD. For example increased WM lesion load has been found to correlate with cognitive impairment in patients with AD [5], and shown to predict the rate of cognitive decline in AD [6]. Furthermore, Rizvi et al. [7] have described WM lesions as affecting cognition both directly and indirectly through grey matter thickness, similarly for both cognitively healthy and cognitively impaired (MCI/AD). However, comparing the differences of the effects on cognitive functions between the groups has not typically been the main focus. Increasing our knowledge of the effects that vascular changes can have on cognition would be especially relevant for clinicians working in cognitive assessment with MCI and AD patients. Thus, our purpose in the current study was to examine if WM changes are related to cognitive function in older adults, patients with MCI and patients with AD, and whether there would be differences in the effects between the groups.
METHODS
The data used in this study has been collected as part of the DEMPET and TWINPIB research projects conducted at the National PET-Centre in Turku, Finland over many years. Both studies were performed in accordance with relevant guidelines and regulations and were approved by the Joint Ethical Committee of the University of Turku and Turku University City Hospital. The diagnosis of MCI was performed according to the Petersen et al. criteria [8], whereas patients with AD satisfied the DSM-IV criteria for dementia as well as the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association) criteria for probable AD [9]. All participants underwent an extensive neuropsychological assessment (for an example, see Kemppainen et al. [10]). The Finnish version of the CERAD test battery [11] was included in this assessment, but was not used for group classification. In the current study a minimum score of 25 in the Mini-Mental State Examination was required for inclusion in the healthy adult control group, with two 24–point exceptions being admitted in light of their adequate level of cognitive performance. The final sample consists of 57 healthy adults, 40 patients with MCI, and 52 patients with AD (see Table 1 for demographical and clinical characteristics of study participants). The participants received oral and written information about the study and gave informed consent before their inclusion.
Demographic and Clinical Characteristics of Study Participants
aFrontal MRI data is missing for one participant, and parieto-occipital data for another. b. confluent, beginning confluent; WM, white matter.
A total score for the CERAD test battery (CERAD-TS), computed by summing up the scores from a number of subtests, was first described by Chandler et al. [12], and then expanded by Seo et al. [13]. Both composite scores have shown high test-retest and interrater reliability [13], as well as validity in detecting MCI [13, 14] and AD [13, 15]. The expanded total score by Seo et al. was chosen for the current study. Due to missing data for some of the participants, the Word List Recognition score had to be computed without subtracting false positive recognitions from correct positives. Furthermore, two missing data points were imputed by EM missing data analysis in SPSS.
The MRI scanning of the subjects was performed with 1.5T Philips Intera (Best, the Netherlands). WM changes were analyzed using T2 and FLAIR (fluid attenuated inversion recovery) images. Our focus was on the WM changes in the frontal and parieto-occipital lobes, since visual ratings of these regions have the highest interrater reliability [16]. Two radiologists analyzed the sequences independently on a personal computer, using the Wahlund scale ranging from 0 (no lesions) to 3 (confluent lesions) [16]. The higher one of the two scores was assigned as the final hemispheric WM score. Measures were given for the frontal and parieto-occipital lobes in the left and right hemispheres separately, after which the hemispheric scores were combined to form summary scores. These were further transformed into a three-level categorical variable ranging from none/focal changes (0–2 points in the hemispheric summary score), through beginning confluent changes (3–4 points) to diffuse changes (5–6 points). This was performed for both the frontal and parieto-occipital regions.
For statistical analyses, we first examined any potential age, education, and gender effects by conducting a series of parametric (independent samples
RESULTS
Demographic and clinical characteristics of study participants are presented in Table 1. There were some differences regarding the demographic characteristics, but of a very small magnitude: The control group was younger than the MCI group, t(95) = –2.27,
As would be expected, the control group had higher cognitive performance than the MCI group, t(95) = 3.17,
The results regarding the analysis of the main study variables can be found in Table 2. Concerning cerebrovascular pathology, no significant main effects of WM pathology on cognitive performance were encountered. However, a significant interaction effect between the group and level of frontal WM changes was found. The control group contained a single participant with diffuse WM changes, who also had unusually high cognitive test scores. In order to examine whether this single participant may have affected the results, we removed the participant and rerun the analysis. After this, the interaction term between group and level of frontal WM changes no longer reached the 0.05 alpha level, but was very close. Moreover, the effect size was still nearly moderate, which indicates that the interaction explained a considerable amount of variation. This trend level interaction was due to the fact that AD patients with confluent WM lesions performed worse than those with less WM changes.
Univariate ANOVA results of the study variables
aThe results have been adjusted for education and age. bThe results have been adjusted for education and age, and an outlier has been removed. cTrend-level significance.
DISCUSSION
The focus of this study was to examine if WM pathology, specifically in frontal and occipito-parietal areas, is related to cognitive function in older adults, patients with MCI and patients with AD, as measured with the CERAD-TS. These areas were chosen since visual ratings of them have shown the highest interrater reliability [16]. As expected, significant differences in cognitive function were found between all three groups; highest performances were found in the control group, intermediate performances in the MCI group and lowest test scores in the AD group. Additionally, a significant interaction effect was found between group and the level of frontal WM changes. After removing an outlier from the control group, the interaction term fell below statistical significance, but only marginally so (
Cognitive performance (as measured by the CERAD Total Score, range 0–115) in the three patient groups as a function of frontal white matter pathology. Estimated marginal means reported. MCI, mild cognitive impairment; AD, Alzheimer’s disease.
Parieto-occipital WM changes were not related to cognitive performance in any of the groups. One explanation for this might be the fact that most of the CERAD subtests place relatively more emphasis on verbal than visuospatial functions. Thus, multi-domain cognitive analyses would be recommended in the future.
In addition to a cross-sectional design, uneven group sizes are a limitation of the current study. The none/focal WM changes group is overrepresented, whereas the diffuse WM changes group is substantially smaller in size, which can amplify the possibility of a type II error.
The effects of WM pathology on cognition in cognitively healthy adults, MCI, and AD have been examined in some studies, though comparing the differences of the effects between groups has not typically been the main focus. For example, previous studies have shown connections between WM changes and the rate of cognitive decline in AD [6], and the incidence of dementia in elderly individuals [17], as well as correlations between WM lesions in the corpus callosum and the fornices and global cognition in AD patients [5].
Furthermore, these phenomena have also been examined from another perspective, as some studies have studied the effects of amyloid pathology in patients with subcortical vascular dementia (for a review, see [18]). Park et al. [19] found that cognitive performance in immediate and delayed memory tasks was significantly worse in subcortical vascular dementia patients with extreme amyloidosis, suggesting that amyloid pathology has an independent effect on memory performance in the presence of cerebrovascular pathology. It is noteworthy, that while some studies have reported that cerebrovascular and AD pathology measures were uncorrelated [20], other studies have suggested the possibility for independent processes as well as interactions between these pathologies [21].
In summary, the current study builds on previous research concerning the interplay between AD and cerebrovascular pathology, and results indicate that concomitant frontal WM lesions in AD patients may lead to additive decline in cognitive functioning. To our knowledge we are the first ones to report this additivity of cognitive impairments in relation to specifically frontal WM lesions in AD. Furthermore, from a clinical perspective it is noteworthy that these can be detectable even when using rough general-level cognitive measures.
Further studies are needed to elucidate whether domain-specific effects can be found using more sophisticated neuropsychological instruments. Using quantitative methods that allow for more localized analyses of vascular pathology could also shed light on the relationship between vascular pathology and its cognitive repercussions in AD.
